These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29310997)

  • 1. Neurohormonal Imbalance: A Neglected Problem-And Potential Therapeutic Target-In Acute Heart Failure.
    Goldsmith SR; Bart BA; Pin A IL
    Curr Probl Cardiol; 2018 Jul; 43(7):294-304. PubMed ID: 29310997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new approach to treatment of acute heart failure.
    Goldsmith SR
    J Cardiol; 2016 May; 67(5):395-8. PubMed ID: 26946929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurohormonal activation in congestive heart failure and the role of vasopressin.
    Chatterjee K
    Am J Cardiol; 2005 May; 95(9A):8B-13B. PubMed ID: 15847852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine vasopressin antagonism in heart failure: Current status and possible new directions.
    Goldsmith SR
    J Cardiol; 2019 Jul; 74(1):49-52. PubMed ID: 30904236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel strategies: challenge loop diuretics and sodium management in heart failure--part II.
    Di Pasquale P; Sarullo FM; Paterna S
    Congest Heart Fail; 2007; 13(3):170-6. PubMed ID: 17541312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neurohormonal factors in heart failure. II].
    Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
    Rev Esp Cardiol; 1996 May; 49(5):317-27. PubMed ID: 8744385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and clinical spectrum of acute congestive heart failure.
    Shah M; Ali V; Lamba S; Abraham WT
    Rev Cardiovasc Med; 2001; 2 Suppl 2():S2-6. PubMed ID: 12439355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of vasopressin in congestive heart failure.
    Goldsmith SR
    Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S19-23. PubMed ID: 16970149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuro-hormonal mechanisms in heart insufficiency--from physiopathology to treatment].
    Cerqueira-Gomes M; Polónia J; Brandão F; Ramalhão C; de Faria DB
    Rev Port Cardiol; 1989 Feb; 8(2):129-48. PubMed ID: 2576635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neuro-hormonal mechanisms in heart failure -- from physiopathology to treatment].
    Cerqueira-Gomes M; Polónia J; Brandão F; Ramalhão C; da Faria DB
    Rev Port Cardiol; 2001 May; 20 Suppl 5():V-99-122; discussion V-123-5. PubMed ID: 11515306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure.
    Aspromonte N; Cruz DN; Valle R; Bonello M; Tubaro M; Gambaro G; Marchese G; Santini M; Ronco C
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1049-63. PubMed ID: 21599566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.
    Albaghdadi M; Gheorghiade M; Pitt B
    Eur Heart J; 2011 Nov; 32(21):2626-33. PubMed ID: 21672933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohormonal activation in heart failure with reduced ejection fraction.
    Hartupee J; Mann DL
    Nat Rev Cardiol; 2017 Jan; 14(1):30-38. PubMed ID: 27708278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators.
    Martin FL; Chen HH; Cataliotti A; Burnett JC
    Rev Cardiovasc Med; 2008; 9(1):39-45. PubMed ID: 18418308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neurohormonal activity in heart insufficiency].
    Svanegaard J; Johansen JB; Thayssen P; Haghfelt T
    Ugeskr Laeger; 1993 Jun; 155(23):1784-8. PubMed ID: 8317027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.
    Reed BN; Street SE; Jensen BC
    Heart Fail Clin; 2014 Oct; 10(4):543-57. PubMed ID: 25217430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?
    Goldsmith SR; Udelson JE; Gheorghiade M
    J Card Fail; 2018 Feb; 24(2):112-114. PubMed ID: 29329950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial.
    Goldsmith SR; Burkhoff D; Gustafsson F; Voors A; Zannad F; Kolkhof P; Staedtler G; Colorado P; Dinh W; Udelson JE
    J Card Fail; 2021 Feb; 27(2):233-241. PubMed ID: 33188886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies: challenge loop diuretics and sodium management in heart failure--Part I.
    Pasquale PD; Sarullo FM; Paterna S
    Congest Heart Fail; 2007; 13(2):93-8. PubMed ID: 17392613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
    Mentz RJ; Stevens SR; DeVore AD; Lala A; Vader JM; AbouEzzeddine OF; Khazanie P; Redfield MM; Stevenson LW; O'Connor CM; Goldsmith SR; Bart BA; Anstrom KJ; Hernandez AF; Braunwald E; Felker GM
    JACC Heart Fail; 2015 Feb; 3(2):97-107. PubMed ID: 25543972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.